Last reviewed · How we verify
Intradetrusor Botox Injections
Botulinum toxin injected into the detrusor muscle blocks acetylcholine release at the neuromuscular junction, reducing involuntary bladder contractions.
Botulinum toxin injected into the detrusor muscle blocks acetylcholine release at the neuromuscular junction, reducing involuntary bladder contractions. Used for Overactive bladder with urge incontinence, Neurogenic detrusor overactivity in spinal cord injury patients.
At a glance
| Generic name | Intradetrusor Botox Injections |
|---|---|
| Sponsor | The Methodist Hospital Research Institute |
| Drug class | Neurotoxin; botulinum toxin type A |
| Target | SNARE complex (synaptosomal-associated protein); acetylcholine release machinery |
| Modality | Biologic |
| Therapeutic area | Urology; Neurology |
| Phase | FDA-approved |
Mechanism of action
Botulinum toxin type A cleaves SNARE proteins required for acetylcholine vesicle release, thereby inhibiting parasympathetic signaling to the detrusor muscle. This reduces the frequency and intensity of involuntary bladder contractions, increasing bladder capacity and reducing urinary urgency and incontinence episodes.
Approved indications
- Overactive bladder with urge incontinence
- Neurogenic detrusor overactivity in spinal cord injury patients
Common side effects
- Urinary tract infection
- Urinary retention
- Hematuria
- Dysuria
- Incomplete bladder emptying
Key clinical trials
- Intradetrusor Botulinum Toxin A for OAB Via 1 Versus 10 Injections: A Randomized Clinical Trial (PHASE4)
- Role of Combination Therapy in Women With Refractory Overactive Bladder (NA)
- A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections (PHASE4)
- Children Toxine Botulinum Detrusor Injection in Neurogenic Vesical Hyperactivity Syndrom: Non Inferiority Multicenter Controlled Therapeutic Study Between Two Reported Weight's Doses (PHASE3)
- Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence (PHASE4)
- Assessing the Genitourinary Microbiome of Women With Overactive Bladder Undergoing Onabotulinum Toxin Type A Intradetrusor Injections
- Prophylactic Analgesia for Bladder Botox Injections (PHASE4)
- Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: